Wassil Nowicky
Director of Nowicky Pharma and President
of the Ukrainian Anti-Cancer Institute (
Biography
Wassil Nowicky is the Director of Nowicky Pharma and Presidentof the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) by the end of 1955 from graduation to Diplomingeniueur in 1960 whose title was nostrificated in Austria in 1975. He is the Author of over 300 scientific articles dedicated to cancer research. He is a real member of the New York Academy of Sciences, member of the European Union for Applied Immunology and of the American Association for scientific progress, Honorary Doctor of the Janka Kupala University in Hrodno, doctor honoris causa of the Open international university on Complex Medicine in Colombo, Honorary Member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmacists of America. the award of Austrian Society of sanitary, hygiene and publichealth services and others.
Abstract
One of the most significant problems of cancer therapy is the damaging activity
of anticancer drugs against normal body cells. All attempts to develop a therapeutic agent with a selective cytotoxic effect on tumor cells had no much
success because of the high degree of biological identity between healthy and
malignant cells. The celandine is being used in the medicine over more than 3500years. The first data concerning the therapeutic effect of the juice of celandine in the patient with malignant melanoma were published in Germany in 1536. From that time drugs based on biologically active substances of celandine are widely used to treat cancer and non-cancer disease. It is well known that tumor cell is more negatively charged as compared to normal cell. We have used this feature of the tumor cell to give NSC631570 a property to selectively interact with it, without endangering healthy cells and tissues. The drug is strongly positively charged. Due to this it has an ability to be selectively accumulated in tumor tissue and to inducetumor cell apoptosis only in tumor cells without harmful effect on normal cells.The potent selective antitumor effect of NSC631570 was repeatedly proven by he results of clinical trials. Until now this preparation has been tested on over 100cancer cell lines and on 12 normal cell lines and the results of the studies carried out in more than 120 universities and research centers (in particular at theNational Cancer Institute (the USA)) have shown that the NSC631570 killed only cancer cells without having damaged the normal cells that confirmed its selective and munomodulating effect.
